- Conditions
- Diabetic Kidney Disease (DKD)
- Interventions
- CSL346, Placebo
- Biological · Drug
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 25 Years and older
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 22
- States / cities
- Covina, California • Fresno, California • Lomita, California + 15 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2113–2136
of 33,041
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hypercholesterolemia
- Interventions
- Colesevelam Hydrochloride, Ezetimibe, Simvastatin
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005
- U.S. locations
- 7
- States / cities
- San Diego, California • Ocala, Florida • Overland Park, Kansas + 4 more
- Conditions
- Major Depressive Disorder
- Interventions
- Escitalopram, Placebo
- Drug
- Lead sponsor
- New York State Psychiatric Institute
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Non-Transfusion Dependent Beta-Thalassemia (NTDT)
- Interventions
- REGN7999, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Prostatic Neoplasms
- Interventions
- Apalutamide, Androgen Deprivation Therapy (ADT), Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 2,517 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 44
- States / cities
- La Jolla, California • Los Angeles, California • Orange, California + 36 more
- Conditions
- Healthy Subjects
- Interventions
- Technosphere Inhalation Powder (FDKP), Moxifloxacin, Placebo
- Drug
- Lead sponsor
- Mannkind Corporation
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Tacoma, Washington
- Conditions
- Alzheimers Disease
- Interventions
- Gantenerumab, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 60 Years to 80 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 32
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 28 more
- Conditions
- Enhancement of the ADR During Colonoscopy
- Interventions
- Peppermint Oil, Distilled water
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Gynecologic Cancer
- Interventions
- Lidocaine Bolus Infusion, QL block, Saline Bolus Infusion, Simulated QL block
- Drug · Procedure
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 69 Years · Female only
- Enrollment
- 1 participant
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Venous Thromboembolism
- Interventions
- Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin, Placebo: tablet of Rivaroxaban, Placebo: syringes of Enoxaparin
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,148 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 36 more
- Conditions
- Pain
- Interventions
- Esmolol administered at a rate of 0.5 mg/kg followed by an infusion of 5-15 mcg/kg/min, Placebo Comparator: .9 normal saline
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 64 Years · Female only
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Achondroplasia
- Interventions
- Navepegritide, Placebo for Navepegritide
- Drug
- Lead sponsor
- Ascendis Pharma A/S
- Industry
- Eligibility
- 0 Years to 2 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 3
- States / cities
- Saint Paul, Minnesota • Houston, Texas • Madison, Wisconsin
- Conditions
- Prostate Cancer
- Interventions
- ZD4054 15 mg, Placebo, ZD4054 10 mg
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 447 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2011
- U.S. locations
- 7
- States / cities
- Tucson, Arizona • Los Angeles, California • Gainsville, Florida + 4 more
- Conditions
- Mild Cognitive Impairment, Dementia
- Interventions
- CST-2032, matching placebo for CST-2032, CST-107, matching placebo for CST-107
- Drug
- Lead sponsor
- CuraSen Therapeutics, Inc.
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 14
- States / cities
- Scottsdale, Arizona • Lafayette, California • Boca Raton, Florida + 11 more
- Conditions
- Substance Use Disorders
- Interventions
- Transcranial Alternating Current Stimulation at 10 Hz, Transcranial Alternating Current Stimulation at 40 Hz, Active sham transcranial alternating current stimulation
- Device
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Raleigh, North Carolina
- Conditions
- Heavy Menstrual Bleeding, Uterine Fibroid
- Interventions
- Relugolix, Estradiol/norethindrone acetate, Relugolix placebo, Estradiol/norethindrone acetate placebo
- Drug
- Lead sponsor
- Myovant Sciences GmbH
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 382 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 89
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 78 more
- Conditions
- Breast Neoplasms, Neoplasm Metastasis
- Interventions
- Temsirolimus (CCI-779) for 34 months, Letrozole for 34 months
- Drug
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,236 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 112
- States / cities
- Hoover, Alabama • Huntsville, Alabama • Tucson, Arizona + 98 more
- Conditions
- Hypercholesterolemia, Flushing
- Interventions
- Apple pectin, Aspirin 325 mg, Placebo
- Other · Drug
- Lead sponsor
- Patrick Moriarty, MD, FACP, FACC
- Other
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Opioid Related Disorders, Opioid Dependence, Opioid Addiction
- Interventions
- Buprenorphine/naloxone, Clonidine, Tramadol ER
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Healthy
- Interventions
- LY3461767 - SC, LY3461767 - IV, Placebo - SC
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 2
- States / cities
- Daytona Beach, Florida • Dallas, Texas
- Conditions
- Postoperative Pain, Acute
- Interventions
- Active Percutaneous Auricular Neuromodulation with NSS-2 Bridge, Sham Treatment
- Device
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Preterm Infant, Development, Infant, Nutrition
- Interventions
- Prebiotic, Dextrose Control
- Dietary Supplement
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- 7 Days to 10 Days
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Scar Prevention, Scar Reduction
- Interventions
- AZX100 Drug Product, Placebo
- Drug
- Lead sponsor
- Capstone Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania • Austin, Texas
- Conditions
- Post Operative Pain
- Interventions
- Sufentanil NanoTab PCA System/15 mcg, Placebo Sufentanil NanoTab PCA System
- Drug
- Lead sponsor
- Talphera, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 419 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Damascus, Maryland